Treatment with THZ1, a covalent CDK7 inhibitor, resulted in cytotoxic activity against MYCN-amplified NB cells and impaired tumor growth in xenograft mouse models, as it selectively impairs global transcription in these cells by targeting super-enhancer-associated genes related to the malignant state, such as MYCN and ALK [109]. The gene discussed is MYCN; the disease is neoplasm.